A democratized platform for mapping the spatial epigenome in tissue
用于绘制组织空间表观基因组图谱的民主化平台
基本信息
- 批准号:10822023
- 负责人:
- 金额:$ 139.08万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-19 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:ATAC-seqAddressAdoptionAnatomyAreaBar CodesBindingBioinformaticsBiologicalBiological AssayBiologyBiomedical ResearchBiotechnologyBrainCancer BiologyCapitalCardiacCardiovascular DiseasesCause of DeathCell CommunicationCellsChromatinClosure by clampCollaborationsComplexComputer softwareCustomCutaneous LymphomaDNADNA sequencingDataData AnalysesData SetDemocracyDevelopmentDimensionsDiseaseDisease ProgressionElementsEmbryoEpigenetic ProcessEquipmentFeedbackGene ExpressionGeneticGenetic TranscriptionGenomeGerminomaGoalsGrantHealthcareHumanImmuneIndustry StandardLocationMalignant NeoplasmsManualsManuscriptsMapsMarketingMethodsMicrofluidic MicrochipsMicrofluidicsMusPathologyPerformancePhasePhenotypePlayPopulationPositioning AttributePriceProteomicsProtocols documentationPublicationsRNAReproducibilityResearchResearch PersonnelResistanceResolutionRoleRunningSamplingScientistSiteSmall Business Innovation Research GrantSpottingsStandardizationStructureTechnologyTimeTissuesTrainingTransposaseUniversitiesUntranslated RNAXCL1 genebioinformatics toolbrain tissuecancer therapycardiovascular disorder therapycare burdencommercial applicationcommercializationcomputational pipelinescomputerized data processingcostdata analysis pipelinedata explorationdata integrationdata reductiondesigneffective therapyepigenomeepigenomicsgenome-wideimmune cell infiltrateimprovedinnovationinsightinterestmelanomanext generationnext generation sequencingnovelnovel strategiespatient responseprognostic tooltherapeutic effectivenesstherapy resistanttooltranscription factortranscriptome sequencingtranscriptomicstreatment responsetumortumor microenvironmentuser-friendly
项目摘要
PROJECT SUMMARY
AtlasXomics Inc. is commercializing the next generation of spatial biology tools to help
researchers understand the epigenetic mechanisms of disease. The goal of this SBIR grant is to
commercialize a product suite of hardware, consumables, and software to spatially interrogate
tissue and generate a new layer of data for better understanding gene expression modulation in
tissue. The development of novel research tools is critical to address the significant healthcare
burden posed by cancer and cardiovascular disease. Epigenetic dysregulation plays a significant
role in disease development and response to therapy, but current technologies are inadequate
for capturing epigenetic changes in interacting cell populations. AtlasXomics developed and
established proof-of-concept performance of the spatial ATAC-seq (Assay for Transposase
Accessible Chromatin) assay. In the Phase I, AtlasXomics successfully transferred the academic
protocol into a commercial workflow and met industry standards for ATAC-seq quality in mouse
and human cancer tissues. The Company introduced the first commercial epigenomics assay to
the market in June 2022.
In this proposed Phase II, the Company will increase the price performance of the assay to
address feedback from customers and prospects: cover a larger area of tissue, increase cellular
resolution, and establish a user-friendly, interactive data analysis suite that enables researchers
to seamlessly analyze data. The product of this SBIR will be an all-in-one kit that integrates a
suite of hardware, consumables, and bioinformatics tools to enable scientists to explore the
epigenetic dimension of disease pathology., e.g., characterize tumor and immune cells spatially
in the tissue microenvironment. The product will democratize broad adoption of the spatial
epigenomics platform because it does not require costly custom equipment and the proposed
bioinformatics workflow will also simplify the analysis of the large epigenomics datasets generated
by the assay. This product will help scientists to gain biological insight into the spatial epigenetic
mechanisms that drive disease progression and therapy response.
项目摘要
Xomics Inc.正在将下一代空间生物学工具商业化,
研究人员了解疾病的表观遗传机制。该SBIR赠款的目标是
将硬件、耗材和软件的产品套件商业化,
组织,并产生一个新的数据层,以更好地了解基因表达调控,
组织.开发新的研究工具对于解决重大的医疗保健问题至关重要。
癌症和心血管疾病造成的负担。表观遗传失调在
在疾病发展和治疗反应中的作用,但目前的技术还不够
用于捕获相互作用的细胞群体中的表观遗传变化。Xomics公司开发了
建立了空间ATAC-seq(转座酶测定)的概念验证性能
染色质)测定。在第一阶段,Xomics成功地将学术
该方案转化为商业工作流程,并符合小鼠ATAC-seq质量的行业标准
和人类癌症组织。该公司推出了第一个商业表观基因组学检测,
2022年6月的市场。
在此拟议的第二阶段,公司将提高检测试剂盒的性价比,
解决客户和潜在客户的反馈:覆盖更大的组织面积,增加细胞
解决方案,并建立一个用户友好的,交互式的数据分析套件,使研究人员
无缝地分析数据。该SBIR的产品将是一个一体化套件,
一套硬件、耗材和生物信息学工具,使科学家能够探索
疾病病理学的表观遗传维度,例如,在一个实施例中,在空间上表征肿瘤和免疫细胞
在组织微环境中。该产品将民主化的空间广泛采用
表观基因组学平台,因为它不需要昂贵的定制设备,
生物信息学工作流程还将简化生成的大型表观基因组学数据集的分析
通过分析。该产品将帮助科学家获得空间表观遗传的生物学见解
驱动疾病进展和治疗反应的机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jeffrey Sabina其他文献
Jeffrey Sabina的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jeffrey Sabina', 18)}}的其他基金
Dissecting the wiring of yeast's glucose sensing circuit
剖析酵母葡萄糖传感电路的接线
- 批准号:
7476271 - 财政年份:2006
- 资助金额:
$ 139.08万 - 项目类别:
Dissecting the wiring of yeast's glucose sensing circuit
剖析酵母葡萄糖传感电路的接线
- 批准号:
7271369 - 财政年份:2006
- 资助金额:
$ 139.08万 - 项目类别:
Dissecting the wiring of yeast's glucose sensing circuit
剖析酵母葡萄糖传感电路的接线
- 批准号:
7158713 - 财政年份:2006
- 资助金额:
$ 139.08万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 139.08万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 139.08万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 139.08万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 139.08万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 139.08万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 139.08万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 139.08万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 139.08万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 139.08万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 139.08万 - 项目类别:
Research Grant